Cargando…

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022

OBJECTIVES: We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022. METHODS: We used Cox proportional hazard models, where vaccine status was included...

Descripción completa

Detalles Bibliográficos
Autores principales: Veneti, Lamprini, Berild, Jacob Dag, Watle, Sara Viksmoen, Starrfelt, Jostein, Greve-Isdahl, Margrethe, Langlete, Petter, Bøås, Håkon, Bragstad, Karoline, Hungnes, Olav, Meijerink, Hinta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991321/
https://www.ncbi.nlm.nih.gov/pubmed/36893942
http://dx.doi.org/10.1016/j.ijid.2023.03.004
_version_ 1784902128624467968
author Veneti, Lamprini
Berild, Jacob Dag
Watle, Sara Viksmoen
Starrfelt, Jostein
Greve-Isdahl, Margrethe
Langlete, Petter
Bøås, Håkon
Bragstad, Karoline
Hungnes, Olav
Meijerink, Hinta
author_facet Veneti, Lamprini
Berild, Jacob Dag
Watle, Sara Viksmoen
Starrfelt, Jostein
Greve-Isdahl, Margrethe
Langlete, Petter
Bøås, Håkon
Bragstad, Karoline
Hungnes, Olav
Meijerink, Hinta
author_sort Veneti, Lamprini
collection PubMed
description OBJECTIVES: We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022. METHODS: We used Cox proportional hazard models, where vaccine status was included as a time-varying covariate and models were adjusted for age, sex, comorbidities, residence county, birth country, and living conditions. RESULTS: The VE against Delta infection peaked at 68% (95% confidence interval [CI]: 64-71%) and 62% (95% CI: 57-66%) in days 21-48 after the first dose among those aged 12-15 years and 16-17 years, respectively. Among those aged 16-17 years who received two doses, the VE against Delta infection peaked at 93% (95% CI: 90-95%) in days 35-62 and decreased to 84% (95% CI: 76-89%) in ≥63 days after vaccination. We did not observe a protective effect against Omicron infection after receiving one dose. Among those aged 16-17 years, the VE against Omicron infection peaked at 53% (95% CI: 43-62%) in 7-34 days after the second dose and decreased to 23% (95% CI: 3-40%) in ≥63 days after vaccination. CONCLUSION: We found a reduced protection after two BNT162b2 vaccine doses against any Omicron infection compared to Delta. Effectiveness decreased with time from vaccination for both variants. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during the Omicron dominance.
format Online
Article
Text
id pubmed-9991321
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-99913212023-03-08 Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 Veneti, Lamprini Berild, Jacob Dag Watle, Sara Viksmoen Starrfelt, Jostein Greve-Isdahl, Margrethe Langlete, Petter Bøås, Håkon Bragstad, Karoline Hungnes, Olav Meijerink, Hinta Int J Infect Dis Article OBJECTIVES: We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022. METHODS: We used Cox proportional hazard models, where vaccine status was included as a time-varying covariate and models were adjusted for age, sex, comorbidities, residence county, birth country, and living conditions. RESULTS: The VE against Delta infection peaked at 68% (95% confidence interval [CI]: 64-71%) and 62% (95% CI: 57-66%) in days 21-48 after the first dose among those aged 12-15 years and 16-17 years, respectively. Among those aged 16-17 years who received two doses, the VE against Delta infection peaked at 93% (95% CI: 90-95%) in days 35-62 and decreased to 84% (95% CI: 76-89%) in ≥63 days after vaccination. We did not observe a protective effect against Omicron infection after receiving one dose. Among those aged 16-17 years, the VE against Omicron infection peaked at 53% (95% CI: 43-62%) in 7-34 days after the second dose and decreased to 23% (95% CI: 3-40%) in ≥63 days after vaccination. CONCLUSION: We found a reduced protection after two BNT162b2 vaccine doses against any Omicron infection compared to Delta. Effectiveness decreased with time from vaccination for both variants. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during the Omicron dominance. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023-05 2023-03-08 /pmc/articles/PMC9991321/ /pubmed/36893942 http://dx.doi.org/10.1016/j.ijid.2023.03.004 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Veneti, Lamprini
Berild, Jacob Dag
Watle, Sara Viksmoen
Starrfelt, Jostein
Greve-Isdahl, Margrethe
Langlete, Petter
Bøås, Håkon
Bragstad, Karoline
Hungnes, Olav
Meijerink, Hinta
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
title Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
title_full Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
title_fullStr Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
title_full_unstemmed Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
title_short Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
title_sort effectiveness of bnt162b2 vaccine against sars-cov-2 delta and omicron infection in adolescents, norway, august 2021 to january 2022
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991321/
https://www.ncbi.nlm.nih.gov/pubmed/36893942
http://dx.doi.org/10.1016/j.ijid.2023.03.004
work_keys_str_mv AT venetilamprini effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT berildjacobdag effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT watlesaraviksmoen effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT starrfeltjostein effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT greveisdahlmargrethe effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT langletepetter effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT bøashakon effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT bragstadkaroline effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT hungnesolav effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022
AT meijerinkhinta effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022